Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
In this long-term cohort of PBC patients with insufficient response to UDCA, fenofibrate significantly improved cholestatic markers and prognostic scores over time. Given this, and its favourable safety profile, fenofibrate should be further considered as an accessible and affordable second-line therapy in PBC.
Authors
- Yanhong Deng (ORCID: https://orcid.org/0000-0001-6873-8026)
- Mariko Maxwell
- David N. Assis
- Bonnie Chen
- James L. Boyer
- Marina G. Silveira
Institutions
- Yale University (US)
- Yale New Haven Health System (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1111/apt.70574
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00